{"name":"Aprea Therapeutics","slug":"aprea","ticker":"APRE","exchange":"NASDAQ","domain":"aprea.com","description":"Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.","hq":"Boston, MA","founded":0,"employees":"8","ceo":"Christian Schade","sector":"Oncology / DNA Damage Response","stockPrice":0.96,"stockChange":0.08,"stockChangePercent":9.09,"marketCap":"$12M","metrics":{"revenue":285759,"revenueGrowth":-98.4,"grossMargin":0,"rdSpend":23895875,"netIncome":-12599569,"cash":14599347,"dividendYield":0,"peRatio":-1.5,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Eprenetapopt patent cliff ($0.XB at risk)","drug":"Eprenetapopt","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Aprea Therapeutics reported its fourth quarter and full year 2023 financial results, highlighting a net loss of $34.1 million and a cash balance of $123.4 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"deal","headline":"Aprea Therapeutics Announces Collaboration with Merck KGaA to Develop Eprenetapopt in Combination with Merck's KEYTRUDA","summary":"Aprea Therapeutics entered into a collaboration agreement with Merck KGaA to develop eprenetapopt in combination with KEYTRUDA for the treatment of TP53-mutated cancers.","drugName":"","sentiment":"positive"},{"date":"2023-08-02","type":"trial","headline":"Aprea Therapeutics Announces Positive Interim Results from Phase 1/2 Clinical Trial of Eprenetapopt in TP53-Mutated AML and MDS Patients","summary":"Aprea Therapeutics announced positive interim results from its Phase 1/2 clinical trial of eprenetapopt in TP53-mutated AML and MDS patients, demonstrating a complete response rate of 55%.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxPVGtQR21mRUoxd0NqTy1aZUZFTW41TjlVMG5WQ0Q0UVRRMnRWLTBJUFZHbW54VEFFZXp3QnNZcXZOVUdjaE1fV1FtRkFTOTBMNDBRM1FXMkE2UUxpcjJjWWE0TEVWdmt2TGcxbVlCRzNvRW12Y0o5VmFwdVlVZWh0MDdCVEtIS3RTNFdKR19n?oc=5","date":"2026-04-07","type":"pipeline","source":"FinancialContent","summary":"Aprea Therapeutics, Inc. - Common Stock (NQ: APRE - FinancialContent","headline":"Aprea Therapeutics, Inc. - Common Stock (NQ: APRE","sentiment":"neutral"},{"date":"2026-04-01","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxNWkQ3N085ODV6b3Iya3NLeDJ6ODlWUnVwWVZSTE43UVVuVjc0dTA3bXlLSXZ5S0RaaTlmMDRrODJFUkx2dTJWOWZlY2NDMTBTSlQ3SUUzZTU0cTVQQVJLS2ZrTzlRbi1pYVRHR3NKQS1LakN2SHdOUHhjcWJCdnhWUlk0LW9TdlZkVDUxaFExRFFHNzNlRk14TTdkQjlFQWdJUl9RaV9wSDBvcnc3NF9ha2dCcElGMEstSVVjaFZaaHlsRzdCTHc?oc=5","date":"2026-03-17","type":"pipeline","source":"Stock Titan","summary":"Aprea Therapeutics (APRE) files amendment adding EisnerAmper consent to registration - Stock Titan","headline":"Aprea Therapeutics (APRE) files amendment adding EisnerAmper consent to registration","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxPY3I0b3F4Wno3b3ZKQjJ0SWlOeGljMDBaZTdhX0tocVF4SW5jMVNMLVJtbENJanpCTzNjLXhUS0pNTGsyZ2xmRnJ0cGQyaHVBZ2wxdV9CTG01Z3ZpNnFnYnYwZWdzUzFvTU91aUtqd3RteUJjanhOWTVDTHBKcGFpMGdjZ05lM3ZFZ0ZLaDJMa1ZvVHpOZ0VRdE5kU2lYdEpnZHJEdER3VmxncHR4Ri16ZQ?oc=5","date":"2026-03-16","type":"pipeline","source":"Stock Titan","summary":"Aprea Therapeutics (Nasdaq: APRE) posts 2025 loss and oncology pipeline update - Stock Titan","headline":"Aprea Therapeutics (Nasdaq: APRE) posts 2025 loss and oncology pipeline update","sentiment":"neutral"},{"date":"2026-03-16","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-16","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQS2VKS21XU2tnTkRPRFNiQ3R0aE1kR1U4RllzZE5uOVFwWW1yY2xEaHB6UUkzMUdGQmlQRVk4dVlWeTN0ZnFnak5hd2hPc3liTUNhak5XTWFqN1NNUjFwTm1FYU9OS3Z3TGFyQzV1bTFqZGVOUlhyU2QyM3VaNkhhRmN1T2ZiNjNXNWNPZmdvNzZhTFE3M1hpUi1MWlMtMVJ6NGdZNUJralFqOFg4d1hlanBpTTM?oc=5","date":"2026-02-20","type":"pipeline","source":"Benzinga","summary":"12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga","headline":"12 Health Care Stocks Moving In Friday's Pre-Market Session","sentiment":"neutral"},{"date":"2026-02-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwJBVV95cUxNT2M3bThwa3dTOW05ZkNGdW10dHl3VUZWZDVUbl9EX1E2Zkp0dWE0eE1WR1NtdjNlek5oTnoxVDdwcjFmVTNEcTMwTlc2Szd2amRJaGlqVjNSWktLRWx0aHNNeUpiR0ZVbnlTdU9nVXBfYThvVDlfTTFkd280eFVOcThBMVowT3ZFSzRhdV9uOTF5ZC1QQnVNN3dodlNOQ0VjUTlKVkpZMGpyaXlkdlFFdHlnTVJhZWJXeFZvejc5d1pTbU9FQ2NLcEJkQzZSaHBNS1dMLUR1LWpVTkp6bTVLT1I5LTRuQU5YbHF3dmEyTG1YcUdqUmRlYUpiRlQ5aXhiVUhodG5maGVYRDR2OEhqNU15cnJuR2dwZDRVdDdEYXRWVmozZFlTeVZ0cUVWSGV0TFUxemoyXy02VjdEdjRzRG5RLVhURGs?oc=5","date":"2026-02-13","type":"patent","source":"Finansavisen","summary":"Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth - Finansavisen","headline":"Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8AFBVV95cUxQbGxKU1dCUHlNcnVRak1mOVJTdktfSURRbHZCWGJ6akkwbENNVW9ESGdBUDVQQ2JNNTZuMFB6RDFCajJCS1ZMTEoxNHI4OFNGQmkteWdyT04yNEwyMEtkM3RPNnJwUlhLeVVLbHNUc3NsUk1uMlh4a1VrdXJGZVVXNFBNd3pIdFllZXpMMXI1NkZxODJIcmFVMjJLOTQ1RnJLS1pYRmx1d1RRT3FTdEdHeFNXQ01HSWdYVEV6T0ZnZVVwUElNdzFuY1Q4Tk5fZDhWRjE3dFJlcEQyN2F2Z3FvalJyVDBSQkMxcGRhTzRzWEg?oc=5","date":"2026-02-04","type":"pipeline","source":"GlobeNewswire","summary":"Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor - GlobeNewswire","headline":"Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxONlYxTy1LYXhfWVB1S3RBVU5pVVdwNUptbnBkSHppb211WG1DWkIwVVByMmtDTlN1X3lhSDJ6RDlQaVRWYXg4eTV6VTduZ1EtWlJqaTd1VnV0dzg4LUZWcnU1Sm9aYVVPTjJ2MEdIUnNGNzFUMHJfaFVQU1IxY3Fpc1VUclNxNVF4Wm53QjktM19GRlJWOHRyZThWX2stNFpIUFBzZUdxdnZMZw?oc=5","date":"2026-01-29","type":"trial","source":"StockInvest.us","summary":"Aprea Therapeutics Shares Slide After Phase 1 Cancer Drug Results Disappoint - StockInvest.us","headline":"Aprea Therapeutics Shares Slide After Phase 1 Cancer Drug Results Disappoint","sentiment":"negative"},{"date":"2026-01-29","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-03","type":"pipeline","source":"simplywall.st","summary":"Aprea Therapeutics, Inc. (NASDAQ:APRE): Is Breakeven Near? - simplywall.st","headline":"Aprea Therapeutics, Inc. (NASDAQ:APRE): Is Breakeven Near?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTFBWM0R4TGR2MEN6TUZzVmVwdUZiU1NBeUxya1pobFoxT3YwQmFiSFJ5QlpROHg0Uk1UN2F0WWROVzRGMUJYUGEzdFI1TlNqLVVnNTdVSld1QkpjdjQ4YWg1bHpDUWdMRDBv?oc=5","date":"2025-07-09","type":"regulatory","source":"MarketBeat","summary":"Aprea Therapeutics (APRE) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $APRE - MarketBeat","headline":"Aprea Therapeutics (APRE) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $APRE","sentiment":"positive"}],"patents":[{"drugName":"Eprenetapopt","drugSlug":"eprenetapopt","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bayer AG","Merck & Co.","Novartis AG"],"therapeuticFocus":["Oncology","DNA Damage Response"],"financials":{"source":"sec_edgar+yahoo","revenue":0,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":0},{"period":"2024-12-31","value":0},{"period":"2023-12-31","value":0},{"period":"2022-12-31","value":0}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":23895875,"rdSpendHistory":[{"period":"2025-12-31","value":7043035},{"period":"2024-12-31","value":9363537},{"period":"2023-12-31","value":7627491},{"period":"2022-12-31","value":16402273}],"sgaSpend":6476560,"operatingIncome":-13233836,"operatingIncomeHistory":[{"period":"2025-12-31","value":-13233836},{"period":"2024-12-31","value":-14319655},{"period":"2023-12-31","value":-15471963},{"period":"2022-12-31","value":-37372044}],"netIncome":-12599569,"netIncomeHistory":[{"period":"2025-12-31","value":-12599569},{"period":"2024-12-31","value":-12958711},{"period":"2023-12-31","value":-14286756},{"period":"2022-12-31","value":-112662027}],"eps":-2.35,"epsHistory":[{"period":"2024-12-31","value":-2.35},{"period":"2023-12-31","value":-3.95},{"period":"2022-12-31","value":-67.99},{"period":"2021-12-31","value":-34.8}],"cash":14599347,"cashHistory":[{"period":"2025-12-31","value":14599347},{"period":"2024-12-31","value":22849885},{"period":"2023-12-31","value":21606820},{"period":"2022-12-31","value":28786647}],"totalAssets":15933401,"totalLiabilities":3491719,"totalDebt":0,"equity":12441682,"operatingCashflow":-12894439,"operatingCashflowHistory":[{"period":"2025-12-31","value":-12894439},{"period":"2024-12-31","value":-13556718},{"period":"2023-12-31","value":-12177608},{"period":"2022-12-31","value":-25011136}],"capex":-15478,"capexHistory":[{"period":"2024-12-31","value":-15478},{"period":"2023-12-31","value":-93093}],"freeCashflow":-12894439,"dividendsPaid":null,"buybacks":null,"employees":8,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":1637591,"ebit":-2643093,"ebitda":-2637664,"period":"2025-12-31","revenue":0,"epsBasic":-0.32,"netIncome":-2455630,"rdExpense":1008839,"epsDiluted":-0.32,"grossProfit":null,"operatingIncome":-2643093},{"sga":1480319,"ebit":-3117388,"ebitda":-3111959,"period":"2025-09-30","revenue":0,"epsBasic":-0.47,"netIncome":-2972410,"rdExpense":1638917,"epsDiluted":-0.47,"grossProfit":null,"operatingIncome":-3117388},{"sga":1593671,"ebit":-3387773,"ebitda":-3382345,"period":"2025-06-30","revenue":0,"epsBasic":-0.53,"netIncome":-3238870,"rdExpense":1912213,"epsDiluted":-0.53,"grossProfit":null,"operatingIncome":-3387773},{"sga":1764979,"ebit":-4085582,"ebitda":-4080153,"period":"2025-03-31","revenue":0,"epsBasic":-0.66,"netIncome":-3932659,"rdExpense":2483066,"epsDiluted":-0.66,"grossProfit":null,"operatingIncome":-4085582},{"sga":1072776,"ebit":-3226045,"ebitda":-3220617,"period":"2024-12-31","revenue":0,"epsBasic":-0.49,"netIncome":-2894799,"rdExpense":2359086,"epsDiluted":-0.49,"grossProfit":null,"operatingIncome":-3226045}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":0.96,"previousClose":0.88,"fiftyTwoWeekHigh":2.22,"fiftyTwoWeekLow":0.55,"fiftyTwoWeekRange":"0.548 - 2.22","fiftyDayAverage":0.82,"twoHundredDayAverage":1.12,"beta":1.52,"enterpriseValue":-3793828,"forwardPE":-1.5,"priceToBook":0.63,"priceToSales":41.69,"enterpriseToRevenue":-13.28,"enterpriseToEbitda":0.29,"pegRatio":0,"ebitda":-13212121,"ebitdaMargin":0,"freeCashflow":-8564504,"operatingCashflow":-12894439,"totalDebt":0,"debtToEquity":0,"currentRatio":5.63,"returnOnAssets":-41.4,"returnOnEquity":-74.6,"analystRating":"","recommendationKey":"none","numberOfAnalysts":3,"targetMeanPrice":4.4,"targetHighPrice":7,"targetLowPrice":1.2,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":11.6,"institutionHeldPercent":17.6,"sharesOutstanding":12382776,"floatShares":7928189,"sharesShort":103019,"shortRatio":0.13,"shortPercentOfFloat":0.8,"epsTrailing":-1.93,"epsForward":-0.66,"revenuePerShare":0.04,"bookValue":1.52,"officers":[{"age":57,"name":"Dr. Oren  Gilad Ph.D.","title":"Co-Founder, CEO, President & Director"},{"age":68,"name":"Dr. Lars B. Abrahmsen Ph.D.","title":"Senior VP & Chief Scientific Officer"},{"age":57,"name":"Mr. Brian  Wiley","title":"Senior Vice President of Corporate Development & Strategy"},{"age":null,"name":"Dr. Michel  Afargan Ph.D.","title":"Head of Pharmacology Development"},{"age":63,"name":"Mr. Ze'ev  Weiss B.Sc., C.P.A.","title":"Chief Business Advisor"},{"age":56,"name":"Dr. Eugene P. Kennedy F.A.C.S., M.D.","title":"Chief Medical Advisor"},{"age":null,"name":"Ms. Andrea  Epstein","title":"Controller"}],"industry":"Biotechnology","irWebsite":"","website":"https://aprea.com","phone":"215 948 4119"}}